In this work, we systematically studied the genomic, transcriptional, and drug sensitivity profiles of BP-CML primary patient samples with and without RUNX1 mutations. The gene discussed is RUNX1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.